Insmed Inc
$ 158.62
-0.26%
24 Feb - close price
- Market Cap 33,829,437,000 USD
- Current Price $ 158.62
- High / Low $ 160.09 / 152.89
- Stock P/E N/A
- Book Value 3.45
- EPS -6.17
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -2.49 %
- 52 Week High 212.75
- 52 Week Low 60.40
About
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Analyst Target Price
$212.53
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-10-29 | 2025-08-07 | 2025-05-07 | 2025-02-20 | 2024-10-31 | 2024-08-08 | 2024-05-09 | 2024-02-22 | 2023-10-26 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -1.54 | -1.75 | -1.7 | -1.42 | -1.32 | -1.27 | -1.94 | -1.06 | -1.28 | -1.11 | -1.78 | -1.17 |
| Estimated EPS | -1.17 | -1.32 | -1.3 | -1.2 | -1.23 | -1.22 | -1.27 | -1.23 | -1.15 | -1.13 | -1.13 | -1.11 |
| Surprise | -0.37 | -0.43 | -0.4 | -0.22 | -0.09 | -0.05 | -0.67 | 0.17 | -0.13 | 0.02 | -0.65 | -0.06 |
| Surprise Percentage | -31.6239% | -32.5758% | -30.7692% | -18.3333% | -7.3171% | -4.0984% | -52.7559% | 13.8211% | -11.3043% | 1.7699% | -57.5221% | -5.4054% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.9302 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INSM
2026-02-24 17:52:22
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating for Insmed (INSM) with a price target of $230.00. This comes despite negative corporate insider sentiment and a reported GAAP net loss of $328.49 million for the latest quarter, though revenue increased significantly year-over-year. Other analysts have varying opinions, with Barclays also issuing a Buy, while TipRanks – xAI reiterated a Hold rating.
2026-02-24 04:52:22
Insmed Chair and CEO William Lewis sold over $1.6 million in company stock on February 19, 2026, while also exercising options to acquire shares. The sales involved 11,099 shares, and the exercised options added 10,699 shares to his holdings. These transactions come as Insmed shares have seen a significant surge of nearly 99% over the past year, though InvestingPro's Fair Value analysis suggests the stock is currently overvalued.
2026-02-23 13:05:46
HC Wainwright & Co. has reiterated its Buy rating for Insmed (INSM) with a sustained price target of $230. This decision reflects continued analyst confidence despite recent fluctuations in ratings from other firms like Wells Fargo, Morgan Stanley, Barclays, Roth Capital, and RBC Capital. The article highlights Insmed's biopharmaceutical operations across respiratory, immunology, inflammation, and neuro therapeutic areas, with commercial products Arikayce and Brinsupri driving revenue primarily from the United States.
2026-02-23 12:49:37
H.C. Wainwright maintained a Buy rating and $230 price target for Insmed (NASDAQ:INSM), noting positive early 2026 revenue guidance for Brinsupri and potential future upside from expansion into COPD and asthma. Despite an optimistic outlook and strong revenue growth, InvestingPro analysis suggests the stock might be overvalued. Insmed recently reported mixed Q4 2025 earnings, missing EPS expectations but exceeding revenue forecasts.
2026-02-23 12:43:41
H.C. Wainwright reiterated a Buy rating and $230.00 price target for Insmed (NASDAQ:INSM) following the company's early guidance of over $1 billion in 2026 Brinsupri revenue, which is seen as a positive indicator for market access and launch metrics. The firm projects Brinsupri's peak revenue at $5 billion for bronchiectasis, with potential future upside from expansion into COPD and asthma markets. Despite the optimistic outlook, InvestingPro analysis suggests the stock might be overvalued, and Insmed recently reported a mixed Q4 2025, missing EPS but exceeding revenue forecasts.
2026-02-23 11:07:46
Insmed has received marketing authorization from the UK for its non-cystic fibrosis bronchiectasis treatment. This regulatory approval allows Insmed to market the drug in the United Kingdom, expanding its reach for patients with this condition. The treatment is for a chronic lung condition distinct from cystic fibrosis.
